Maravai LifeSciences Holdings, Inc. Class A Common Stock
Here’s whether Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+5.25% over 10 days); strong 1-year return of +261.5%; 3-month momentum positive (+96.4%); rising volume confirms the move (1.48x 30d avg). Concerns: RSI 80 — overbought, elevated pullback risk. Currently 2.6% off its 52-week high. Score: +6/7.
MRVI is in a confirmed uptrend, trading above both its 50-day ($6.26) and 200-day ($4.26) moving averages. With an RSI of 79.8, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +261.5% compares to +20.5% for SPY (beat the market by 241.0%).